Cumulative conception and live-birth rates after in vitro fertilization with and without the use of long, short, and ultrashort regimens of the gonadotropin-releasing hormone agonist buserelin

Tan, Seang‐Lin; Maconochie, Noreen; Doyle, Patricia; Campbell, Stuart; Balen, Adam; Bekir, Jinan; Brinsden, Peter; Edwards, Robert G.; Jacobs, Howard S.

doi:10.1016/0002-9378(94)90291-7

Cited by 81 publications

(43 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Women with previously poor response received either the GnRH-analogue short protocol (20) or the microdose-flare protocol (21), in which the gonadotropins were commenced shortly after commencement of buserelin.…”

Section: Discussionmentioning

confidence: 99%

Pregnancy loss in pregnancies conceived after in vitro oocyte maturation, conventional in vitro fertilization, and intracytoplasmic sperm injection

Buckett

Chian

Dean

et al. 2008

Fertility and Sterility

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Pregnancy loss in pregnancies conceived after in vitro oocyte maturation, conventional in vitro fertilization, and intracytoplasmic sperm injection

Buckett

Chian

Dean

et al. 2008

Fertility and Sterility

View full text Add to dashboard Cite

“…During IVF-ET cycles, most women undergo hypothalamic pituitary suppression prior to the initiation of ovarian stimulation [5]. Hypothalamic pituitary suppression before ovarian stimulation in IVF-ET cycles prevents premature luteinization, increases the number of follicles stimulated, synchronization of follicular development, allows patients scheduling and improves the pregnancy rates [5][6][7].…”

Section: Discussionmentioning

confidence: 99%

“…Hypothalamic pituitary suppression before ovarian stimulation in IVF-ET cycles prevents premature luteinization, increases the number of follicles stimulated, synchronization of follicular development, allows patients scheduling and improves the pregnancy rates [5][6][7]. Generally, gonadotropin suppression is achieved by the use of a gonadotropin releasing hormone agonist (GnRH-a).…”

Section: Discussionmentioning

confidence: 99%

Oral contraceptive pretreatment does not improve outcome in microdose gonadotrophin-releasing hormone agonist protocol among poor responder intracytoplasmic sperm injection patients

Duvan

Berker

Turhan

et al. 2008

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose To compare oral contraceptive (OC) pretreatment plus microdose GnRH-a in flare-up protocol and non-OC microdose GnRH-a in flare-up protocol among poor responder ICSI patients. Methods A retrospective analysis of poor responder ICSI patients. Patients were divided into two groups according to used microdose protocol. Precycle treatment with OC followed by follicular phase administration of 40 μg sc leuprolide acetate (LA) every 12 h beginning on after 2 day pill-free period and rFSH administration was begun on the third day of LA administration (OC-Group, n=26). Alternatively on day 2 after menses, patients were administered similar stimulation regime (non-OC Group, n=27). Results There were no significant differences between groups in the number of oocytes, peak estradiol levels, endometrial thickness, fertilization rates and embryo quality. Implantations and pregnancy rates per embryo transfer were similar. Conclusion OC pretreatment plus microdose GnRHa in flare-up protocol does not offer advantages over non-OC microdose GnRHa in flare-up protocol among poor responder ICSI patients.

show abstract

“…Although per-cycle reporting provides an important indicator of the efficacy of individual treatment events, it is not sufficient to provide data to patients seeking information on outcome after multiple treatments. The few studies that have calculated cumulative success rates after multiple ART or IUI cycles show that, as with the per-cycle rates, age is a major predictor of success; however, success rates decline with subsequent cycles of treatment (3)(4)(5)(6). Diagnosis also affects cumulative rates (7,8).…”

mentioning

confidence: 99%

Cycle 1 as predictor of assisted reproductive technology treatment outcome over multiple cycles: an analysis of linked cycles from the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System online database

Stern¹,

Brown²,

Luke³

et al. 2011

Fertility and Sterility

View full text Add to dashboard Cite

Cumulative conception and live-birth rates after in vitro fertilization with and without the use of long, short, and ultrashort regimens of the gonadotropin-releasing hormone agonist buserelin

Cited by 81 publications

References 20 publications

Pregnancy loss in pregnancies conceived after in vitro oocyte maturation, conventional in vitro fertilization, and intracytoplasmic sperm injection

Pregnancy loss in pregnancies conceived after in vitro oocyte maturation, conventional in vitro fertilization, and intracytoplasmic sperm injection

Oral contraceptive pretreatment does not improve outcome in microdose gonadotrophin-releasing hormone agonist protocol among poor responder intracytoplasmic sperm injection patients

Cycle 1 as predictor of assisted reproductive technology treatment outcome over multiple cycles: an analysis of linked cycles from the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System online database

Contact Info

Product

Resources

About